MICs of clarithromycin against 324 clinical isolates belonging to eight species of slowly growing nontuberculous mycobacteria were determined by using a broth microdilution system. Isolates were inoculated into twofold drug dilutions in Middlebrook 7H9 broth (pH corrected to 7.4) and then incubated at 30°C for 7 days for Mycobacterium marinum and for 14 days for all other species. The MIC for 90%o of the strains (MIC90) was c0.5 ,ug/ml for isolates of Mycobacterium gordonae (6 strains), Mycobacterium scrofulaceum (5 strains), Mycobacterium szulgai (6 strains), and Mycobacterium kansasii (35 strains). MICs for M. marinum (25 strains) and Mycobacterium avium complex (237 strains) were higher, but 100% and 89%o of the strains, respectively, were susceptible to <4 ,ug/ml. In contrast, MICs for five of six M. simiae strains were >8 ,ug/ml, and the range of MICs for Mycobacterium nonchromogenicum varied from .0.125 to 8 ,ug/ml. For the 237 isolates of M. avium complex, the MIC50 was 2 ,ug/ml and the MIC90 was 8 ,ug/ml. MICs for most isolates (77%) were in the 1-to 4-,ug/ml range. For the 80 isolates in this group known to be from AIDS patients, the MIC50 was 4 ,ug/ml and the MIC90 was 8 ,ug/ml. These MIC studies combined with preliminary clinical trials suggest that clarithromycin may be useful for drug therapy of most species of the slowly growing nontuberculous mycobacteria except M. simiae.
Slowly growing nontuberculous mycobacteria, including Mycobacterium kansasii, M. mannum, M. simiae, M. scrofulaceum, M. szulgai, M. gordonae, M. nonchromogenicum, and M. avium-M. intracellulare complex, have been incriminated in various types of human diseases, including skin and soft-tissue infections (20, 22, 26, (28) (29) (30) (31) , pulmonary disease (1, 18, 20, 28, 29, 31, 32) , and disseminated disease in nonimmunocompromised patients and in immunocompromised patients, including those with AIDS (8, 9, 17, 18) . Susceptibility patterns of the slowly growing nontuberculous mycobacteria can be divided into two groups. Isolates of M. mannum, M. gordonae, M. kansasii, and M. nonchromogenicum are usually susceptible to ethambutol, rifampin, sulfonamides, and streptomycin (2, 24, 27, 28) . A second, more resistant group includes isolates of M. avium complex, M. scrofulaceum, M. simiae, and M. szulgai. These isolates are not usually susceptible to first-or second-line antimycobacterial agents and may require combination antibiotic therapy and/or surgical intervention (28, 29, 31, 32) .
Drug therapy in these patients is complex and involves use of drugs with greater incidences of side effects and more toxicity (28) . Thus, newer, less toxic antimicrobial agents are needed for those cases of mycobacterial disease resistant to standard antibiotic regimens. In this study, we tested a large number ofM. avium-M. intracellulare complex isolates and seven other slowly growing nontuberculous mycobacterial species against a new macrolide, clarithromycin (6) .
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The plates were covered, sealed in plastic bags, and incubated in room air at 35°C for 14 days, with the exception (3, 4, 7, (10) (11) (12) (13) (14) 25) . Studies with clarithromycin have shown that it has better absorption, higher levels in serum, and a longer half-life in serum than does erythromycin (11, 13, 14) .
Most previous in vitro studies of clarithromycin against mycobacteria have concentrated on M. avium complex by utilizing either agar dilutions in 7H10 or 7H11 medium (4, 12) or both agar dilutions and BACTEC methodology (15, 21) . By these methods, MICs for approximately 90% of isolates were 54 ,ug/ml. As with other drugs and M. avium complex, MICs for isolates have generally been two-to fourfold lower in broth than in agar (15) . As with erythromycin (19) , clarithromycin was more active at pH 7.4 than at pH 6.8 or 5.0 (15) . The present study confirmed the in vitro susceptibility of M. avium complex to clarithromycin by a broth microdilution technique in 7H9 broth at pH 7.4, with almost 90% of 237 strains inhibited by the tentative susceptible bacterial breakpoint of .4 ,ug/ml. This breakpoint may be problematic with mycobacteria, as MICs for approximately 10% of strains presumably never exposed to clarithromycin are 8 ,ug/ml. An even higher number is noted if a lower pH of medium is used (15) . There are no data to show that the higher MICs for these isolates are consistently this high with repeat testing or that they will result in clinical failure with therapy.
Evaluation of the activity of the newer macrolides against nontuberculous mycobacteria other than M. avium complex is limited. Two previous studies have evaluated M. kansasii, a species which appears to be inhibited by very low concentrations of clarithromycin. Berlin and colleagues (4) utilized an agar dilution method with 7H11 medium (presumed pH 6.8) and reported 100% of 10 isolates of M. kansasii to be inhibited at clarithromycin concentrations of 1.0 ,ug/ml. Biehle and Cavalieri studied 31 strains of M. kansasii using both BACTEC methodology and agar dilutions in 7H11 medium (pH values unknown). The MICs of clarithromycin were 0.25 ,ug/ml for 16 strains and 0.5 ,ug/ml for the remaining 9 strains (5). In the present study all 35 of our M. kansasii isolates were inhibited by <0.25 ,ug/ml at pH 7.4. Some of these isolates were resistant to rifampin (MIC > 1.0 ,ug/ml).
As expected, there was no cross-resistance with clarithromycin.
Previous studies have shown clarithromycin and, to a lesser degree, other new macrolides to be highly active in vitro against rapidly growing mycobacteria (4), especially against Mycobacterium chelonae and Mycobactenum abscessus (7) . Six Metabolic studies have shown that clarithromycin in humans is metabolized in part to a 14-hydroxy metabolite. This metabolite is present in serum at a ratio of 2 to 4:1 (parent drug to metabolite) and is as active as the parent drug against some pathogens (e.g., Haemophilus influenzae) (16) . In vitro studies thus far have not evaluated whether this major metabolite will or does contribute in any way to the activity of clarithromycin for mycobacterial pathogens. Combination studies should be included in future evaluations of this drug against the nontuberculous mycobacteria.
